Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. [electronic resource]
Producer: 20160524Description: 17958-67 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Basic Helix-Loop-Helix Transcription Factors -- genetics
- Biomarkers, Tumor -- blood
- CD4 Lymphocyte Count
- Case-Control Studies
- China
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Interferon-gamma -- blood
- Interleukin-17 -- blood
- Interleukins -- blood
- Male
- Middle Aged
- Multiple Myeloma -- blood
- Neoplasm Staging
- Nuclear Receptor Subfamily 1, Group F, Member 3 -- genetics
- Polymerase Chain Reaction
- RNA, Messenger -- metabolism
- Receptors, Aryl Hydrocarbon -- genetics
- Remission Induction
- T-Lymphocyte Subsets -- drug effects
- Th17 Cells -- drug effects
- Treatment Outcome
- Interleukin-22
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.